Low	O
Concentration	O
of	O
Sodium	B:C0142812
Butyrate	I:C0142812
from	O
Ultrabraid	B:C0038969
+	O
NaBu	B:C0142812
suture	B:C0038969
,	O
Promotes	O
Angiogenesis	B:C0302600
and	O
Tissue	B:C1820201
Remodelling	I:C1820201
in	O
Tendon	B:C0039508
-	O
bones	B:C0561852
Injury	I:C0561852
.	O

Sodium	B:C0142812
butyrate	I:C0142812
(	O
NaBu	B:C0142812
)	O
,	O
a	O
form	O
of	O
short	B:C0015691
-	I:C0015691
chain	I:C0015691
fatty	I:C0015691
acid	I:C0015691
(	O
short	B:C0015691
-	I:C0015691
chain	I:C0015691
fatty	I:C0015691
acid	I:C0015691
)	O
,	O
acts	O
classically	O
as	O
a	O
potent	O
anti-angiogenic	B:C0596087
agent	I:C0596087
in	O
tumour	B:C0027651
angiogenesis	B:C0302600
models	B:C0684309
,	O
some	O
authors	O
demonstrated	O
that	O
low	O
concentrations	O
of	O
NaBu	B:C0142812
may	O
contribute	O
to	O
healing	B:C0043240
of	O
tendon	B:C0039508
-	O
bone	B:C0561852
injury	I:C0561852
in	O
part	O
at	O
least	O
through	O
promotion	O
of	O
tissue	B:C1820201
remodelling	I:C1820201
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
low	O
-	O
range	O
concentrations	O
of	O
NaBu	B:C0142812
using	O
in	B:C1515653
vitro	I:C1515653
and	O
in	B:C1515655
vivo	I:C1515655
assays	B:C0005507
using	O
angiogenesis	B:C0302600
as	O
the	O
primary	O
outcome	O
measure	O
and	O
the	O
mechanisms	O
through	O
which	O
it	O
acts	O
.	O

We	O
demonstrated	O
that	O
NaBu	B:C0142812
,	O
alone	O
or	O
perfused	O
from	O
the	O
UltraBraid	B:C0038969
+	O

NaBu	B:C0142812
suture	B:C0038969
was	O
pro-angiogenic	B:C0302600
at	O
very	O
low	O
-	O
range	O
doses	O
promoting	O
migration	B:C1622501
,	O
tube	B:C2752214
formation	I:C2752214
and	O
cell	B:C2699153
invasion	I:C2699153
in	O
bovine	B:C3667982
aortic	B:C0003483
endothelial	B:C0225336
cells	I:C0225336
(	O
bovine	B:C0225336
aortic	I:C0225336
endothelial	I:C0225336
cells	I:C0225336
)	O
.	O

Furthermore	O
,	O
cell	B:C0007634
exposure	O
to	O
low	O
NaBu	B:C0142812
concentrations	O
increased	O
expression	B:C1171362
of	I:C1171362
proteins	I:C1171362
involved	O
in	O
angiogenic	B:C0302600
cell	B:C0037083
signalling	I:C0037083
,	O
including	O
p-PKC	B:C0257292
β1	I:C0257292
,	O
p-FAK	B:C0059239
,	O
p-ERK1	B:C0082529
/	O
2	B:C0170168
,	O
p	B:C0079904
-	I:C0079904
NFκβ	I:C0079904
,	O
p-PLCγ1	B:C0753837
and	O
p-VEGFR2	B:C0378796
.	O

In	O
addition	O
,	O
inhibitors	B:C0243077
of	O
both	O
VEGFR2	B:C0378796
and	O
PKC	B:C0257292
β1	I:C0257292
blocked	O
the	O
angiogenic	B:C0302600
response	O
.	O

In	O
in	B:C1515655
vivo	I:C1515655
assays	B:C0005507
,	O
low	O
concentrations	O
of	O
NaBu	B:C0142812
induced	O
neovascularization	B:C0027686
in	O
sponge	B:C0021102
implants	I:C0021102
in	O
mice	B:C0026809
,	O
evidenced	O
by	O
increased	O
numbers	O
of	O
vessels	B:C0005847
and	O
haemoglobin	B:C0019046
content	O
in	O
these	O
implants	B:C0021102
.	O

The	O
findings	O
in	O
this	O
study	O
indicate	O
that	O
low	O
concentrations	O
of	O
NaBu	B:C0142812
could	O
be	O
an	O
important	O
compound	O
to	O
stimulate	O
angiogenesis	B:C0302600
at	O
a	O
site	B:C1515974
where	O
vasculature	B:C3714653
is	O
deficient	O
and	O
healing	B:C0043240
is	O
compromised	O
.	O

